Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Inclusion Criteria:

- Adults >/= 18 years old

- Histologically confirmed cutaneous melanoma that is either Stage IIIc (unresectable)
or Stage IV (metastatic) and determined to be BRAF V600E or V600K mutation-positive
(cohort A) or mutation-negative (cohorts B and C)

- ECOG performance status of 0 or 1

- Measurable disease by radiographic or physical examination

- Adequate organ and marrow function

- Willingness to provide consent for biopsies positive or BRAF WT measurable disease,
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate
organ and marrow function

Exclusion Criteria:

- Prior treatment with a BRAF inhibitor or MEK inhibitor

- Any prior Grade ≥ 3 immune-related adverse event while receiving immunotherapy

- Active or prior documented autoimmune disease within the past 2 years

- History of or current risk for retinal vein occlusion (RVO) or central serous
retinopathy (CSR)

- History of or current cardiovascular risk including myocardial infarction, ≥ Class II
congestive heart failure, uncontrolled arrhythmias, or refractory hypertension

- Active, untreated CNS metastases

- Women who are pregnant or lactating